Transcriptomics,Multiomics

Dataset Information

11

Effect of methylphenidate on gene expression profiles of Attention Deficit Hyperactivity Disorder patients and unaffected controls.

ABSTRACT: Attention deficit hyperactivity disorder (ADHD) is a common psychiatric condition of children with a prevalence of 5-10% worldwide. Up to 30% of adults with a history of childhood ADHD maintain symptoms in later life; these adult ADHD patients are severely impaired in social and professional life due to persistence of ADHD core symptoms like impulsivity, attention deficit and hyperactivity as well as frequently observed co-morbidities like alcohol and drug abuse, major depression, bipolar and personality disorders. Pharmaceutical treatment options include methylphenidate (MPH), which is amongst others an inhibitor of the dopamine transporter and therefore increases dopamine levels in the brain. However, not all ADHD patients are MPH responders with clinical features to distinguish responders and non-responders being not at hand so far. Likewise, neurobiological reasons for drug response are still elusive. Here, we examined the global transcriptional response of MPH on lymphoblastoid cell lines (LCLs) derived from ADHD patients and unaffected controls.

OTHER RELATED OMICS DATASETS IN: PRJNA230519

ORGANISM(S): Homo sapiens  

SUBMITTER: Heike Weber   Sarah Kittel-Schneider  Andreas Reif  Claus Juergen Scholz  Ricarda Schwarz  Claus J Scholz 

PROVIDER: E-GEOD-52889 | ArrayExpress | 2014-09-05

SECONDARY ACCESSION(S): GSE52889PRJNA230519

REPOSITORIES: GEO, ArrayExpress

Json Xml

Dataset's files

Source:
Action DRS
E-GEOD-52889.idf.txt Idf
E-GEOD-52889.processed.1.zip Processed
E-GEOD-52889.raw.1.zip Raw
E-GEOD-52889.sdrf.txt Txt
Items per page:
1 - 4 of 4
altmetric image

Publications

A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients.

Schwarz Ricarda R   Reif Andreas A   Scholz Claus-Jürgen CJ   Weissflog Lena L   Schmidt Brigitte B   Lesch Klaus-Peter KP   Jacob Christian C   Reichert Susanne S   Heupel Julia J   Volkert Julia J   Kopf Juliane J   Hilscher Max M   Weber Heike H   Kittel-Schneider Sarah S  

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20140827 3

<h4>Objectives</h4>Methylphenidate (MPH) is a commonly used stimulant medication for treating attention-deficit/hyperactivity disorder (ADHD). Besides inhibiting monoamine reuptake there is evidence that MPH also influences gene expression directly.<h4>Methods</h4>We investigated the impact of MPH treatment on gene expression levels of lymphoblastoid cells derived from adult ADHD patients and healthy controls by hypothesis-free, genome-wide microarray analysis. Significant findings were subseque  ...[more]

Similar Datasets

Unknown Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
2011-01-01 | S-EPMC3243461 | BioStudies
Unknown Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release.
2019-01-01 | S-EPMC6517933 | BioStudies
Unknown The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder.
2018-01-01 | S-EPMC5900374 | BioStudies
Unknown Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder.
2018-01-01 | S-EPMC6205135 | BioStudies
Unknown Neonatal 6-OHDA lesion model in mouse induces Attention-Deficit/ Hyperactivity Disorder (ADHD)-like behaviour.
1000-01-01 | S-EPMC6193955 | BioStudies
Unknown Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.
2010-01-01 | S-EPMC2959002 | BioStudies
Unknown Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
2018-01-01 | S-EPMC6016730 | BioStudies
Unknown Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder.
2009-01-01 | S-EPMC2830226 | BioStudies
Unknown Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
2011-01-01 | S-EPMC3164797 | BioStudies
Unknown Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity.
2017-01-01 | S-EPMC5505611 | BioStudies